TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17489878

Group type: EXPERIMENTAL
Intervention: 40 mg telmisartan/day
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: 150 mg irbesartan/day
Number of subjects: 188

Group type: COMPARATOR
Intervention: Both telmisartan and irbesartan
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Fasting plasma insulin (FPI)
Number of subjects: 188
Study: 15145107

Group type: EXPERIMENTAL
Intervention: Circuit training (CT) for 8 weeks
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (n = 20)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Circuit training (CT)
Number of subjects: 19
Study: 11506246

Group type: EXPERIMENTAL
Intervention: Steroids (oral prednisone 1.0 mg/Kg/day for 2 months, tapered by 0.2 mg/Kg/day every month) plus ramipril (2.5 mg/day for one month, increased by 1.25 mg/day every month)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Ramipril alone
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Steroids plus ramipril
Number of subjects: 134
Study: 9754987

Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg alone
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Caffeine 150 mg alone
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Caffeine 300 mg with zolpidem
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg with caffeine 250 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 8116706

Group type: EXPERIMENTAL
Intervention: Prophylactic penicillin (1 million units of benzylpenicillin intravenously every 4 hours followed by 250 mg of potassium phenoxymethyl penicillin orally twice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1968124

Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 193
Study: 146511

Group type: EXPERIMENTAL
Intervention: Zinc sulphate (0.4 g daily)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 30057283

Group type: EXPERIMENTAL
Intervention: S‐IIV4
Number of subjects: 2247

Group type: COMPARATOR
Intervention: C‐IIV4
Number of subjects: 2247
Study: 29133833

Group type: EXPERIMENTAL
Intervention: Soy protein with isoflavones (SPI)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Soy protein alone without isoflavones (SP)
Number of subjects: 200
Study: 25560477

Group type: EXPERIMENTAL
Intervention: Shoulder Pain and Disability Index (SPADI) pain subscale
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Numeric Pain Rating Scale (NPRS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SPADI
Number of subjects: 0
Study: 23644090

Group type: EXPERIMENTAL
Intervention: Intensive statin therapy (rosuvastatin 40 mg daily)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Standard-of-care lipid-lowering therapy
Number of subjects: 87
Study: 21325901

Group type: EXPERIMENTAL
Intervention: Intrathecal meperidine 12.5 mg (M1)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Intrathecal meperidine 25 mg (M2)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (M0) with bupivacaine 0.5% (10 mg)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Higher doses of meperidine (M1 and M2)
Number of subjects: 72
Study: 19255395

Group type: EXPERIMENTAL
Intervention: Booster seat education and distribution program
Number of subjects: 1010
Study: 17077234

Group type: COMPARATOR
Intervention: 25 microg misoprostol vaginal insert
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: 50 microg misoprostol vaginal insert
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: 100 microg misoprostol vaginal insert
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: 200 microg misoprostol vaginal insert
Number of subjects: 124
Study: 16433203

Group type: EXPERIMENTAL
Intervention: 4-shot allergy vaccine (Pollinex Quattro) containing appropriate allergoids (grass/rye and/or mugwort) adsorbed to L-tyrosine plus a Th1 adjuvant, monophosphoryl lipid A (MPL)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 4-shot allergy vaccine (Pollinex Quattro)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control challenges (similar pollen vaccine without MPL and a tree pollen vaccine with and without MPL)
Number of subjects: 21
Study: 12877821

Group type: EXPERIMENTAL
Intervention: Formoterol 12 microg twice daily in addition to beclomethasone 500 microg twice daily
Number of subjects: 203

Group type: COMPARATOR
Intervention: Beclomethasone 1000 microg twice daily and placebo
Number of subjects: 203
Study: 9950912

Group type: EXPERIMENTAL
Intervention: TNFR:Fc (6 mg/m2)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Endotoxin (2 ng/kg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Coinfusion of TNFR:Fc with endotoxin
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control study day
Number of subjects: 24
Study: 8525409

Group type: EXPERIMENTAL
Intervention: 2% neem oil mixed in coconut oil
Number of subjects: 0
Study: 2098504

Group type: EXPERIMENTAL
Intervention: Lonidamine (LND) in association with radiotherapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lonidamine (LND) in association with Lomustine (CCNU)
Number of subjects: 60
Study: 7191674

Group type: EXPERIMENTAL
Intervention: Cold room environment (temperature 18.9 C or below)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Warm room environment (temperature 22.2 C or above)
Number of subjects: 42
Study: 12377647

Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD)
Number of subjects: 474

Group type: COMPARATOR
Intervention: Topotecan
Number of subjects: 474
Study: 30199447

Group type: EXPERIMENTAL
Intervention: 3 minutes of moderate-intensity RW (cycling at 60% of V[Combining Dot Above]O2max)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 3 minutes of low-intensity RW (cycling at 30% of V[Combining Dot Above]O2max)
Number of subjects: 11

Group type: COMPARATOR
Intervention: 15 minutes of seated rest (control)
Number of subjects: 11
Study: 26115589

Group type: EXPERIMENTAL
Intervention: Carbohydrate‐electrolyte gels (0.7±0.1gkg(‐1) BM)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Energy-free placebo gels
Number of subjects: 8
Study: 25310201

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 50, 70, 100, 150, 200, and 250 mg daily for 5 days
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX)
Number of subjects: 31
Study: 22107609

Group type: EXPERIMENTAL
Intervention: Er:YAG laser irradiation (60 mJ/pulse, 10 pps, 60 sec)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser irradiation (60 mJ/pulse, 10 pps, 60 sec)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Untreated (Control)
Number of subjects: 3
Study: 19696435

Group type: EXPERIMENTAL
Intervention: FFW-L/NBLI and NBLI/FFW-L (combined intervention groups)
Number of subjects: 23

Group type: COMPARATOR
Intervention: wait/NBLI (control group)
Number of subjects: 23
Study: 18508832

Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 30
Study: 16141467

Group type: EXPERIMENTAL
Intervention: Sodium selenite (1,000 microg administered intravenously or orally daily for 3 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 20
Study: 12463577

Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-molecular-weight heparin (enoxaparin)
Number of subjects: 0
Study: 10102147

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (14.2 mg elemental zinc for first 417 patients and 40 mg for remaining 273 patients) for 15 days
Number of subjects: 684

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (4500 microg retinol equivalent) for 15 days
Number of subjects: 684

Group type: COMPARATOR
Intervention: Placebo mixtures for 15 days
Number of subjects: 684
Study: 7778342

Group type: EXPERIMENTAL
Intervention: Beger procedure
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Frey procedure
Number of subjects: 24
Study: 2185023

Group type: EXPERIMENTAL
Intervention: Carbochromen (0.125 mg kg‐1 min‐1 for 40 min i.v.)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Dipyridamole (0.05 mg kg‐1 min‐1 for 10 min i.v.)
Number of subjects: 18
Study: 399859

Group type: EXPERIMENTAL
Intervention: Continuous salbutamol tablets
Number of subjects: 22

Group type: COMPARATOR
Intervention: Intermittent salbutamol tablets
Number of subjects: 22
Study: 31299447

Group type: EXPERIMENTAL
Intervention: Active placebo nasal spray with expectancy-modifying instructions (Protection: the spray protects from experiencing negative emotions)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control group (Sensitization: the spray sensitizes to negative emotions)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control group (Placebo: the spray is a placebo)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control group (Control: no nasal spray)
Number of subjects: 128
Study: 28547075

Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBMT)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Suprascapular nerve (SSN)‐pulsed radiofrequency (RF) therapy
Number of subjects: 59

Group type: COMPARATOR
Intervention: Both PBMT and SSN-pulsed RF therapy
Number of subjects: 59
Study: 26079499

Group type: EXPERIMENTAL
Intervention: Standard haemostasis + TachoSil (Group 2)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard haemostasis (Group 1)
Number of subjects: 70
Study: 23547275

Group type: EXPERIMENTAL
Intervention: Health professionals educational program
Number of subjects: 830
Study: 21599941

Group type: EXPERIMENTAL
Intervention: Specific physiotherapy treatment (10 sessions over 10 weeks)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Physiotherapy advice (2 sessions over 10 weeks)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Specific physiotherapy treatment
Number of subjects: 250

Group type: COMPARATOR
Intervention: Physiotherapy advice
Number of subjects: 250
Study: 19538918

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 182
Study: 16787125

Group type: COMPARATOR
Intervention: Video education/control
Number of subjects: 253

Group type: COMPARATOR
Intervention: Brief telephone calls with no counseling
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Telephone calls with counseling
Number of subjects: 253
Study: 12817519

Group type: EXPERIMENTAL
Intervention: ICL670 2.5 to 80 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ICL670 40- and 80-mg/kg dose levels
Number of subjects: 0
Study: 11111817

Group type: EXPERIMENTAL
Intervention: Extracorporal rheopheresis
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study: 8656257

Group type: EXPERIMENTAL
Intervention: CMF for three consecutive courses on months 1 to 3 (CMFx3)
Number of subjects: 1554

Group type: COMPARATOR
Intervention: CMF for 6 consecutive courses on months 1 to 6 (CMF x 6)
Number of subjects: 1554

Group type: COMPARATOR
Intervention: CMFx3 plus three single courses of reintroduction CMF given on months 6, 9, and 12
Number of subjects: 1554

Group type: COMPARATOR
Intervention: CMFx6 plus three single courses of reintroduction CMF given on months 9, 12, and 15
Number of subjects: 1554

Group type: EXPERIMENTAL
Intervention: Reintroduction chemotherapy
Number of subjects: 1554

Group type: EXPERIMENTAL
Intervention: Reintroduction chemotherapy for women aged > or = 40 years
Number of subjects: 1554

Group type: COMPARATOR
Intervention: CMFx3 for women aged less than 40 years
Number of subjects: 1554

Group type: COMPARATOR
Intervention: CMFx3 for patients with ER-negative tumors
Number of subjects: 1554
Study: 2069512

Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 6340601

Group type: EXPERIMENTAL
Intervention: Ceftazidime 1.5 g daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ceftazidime 3 g daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 30
Study: 31238907

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive-behavioral treatment (9 sessions)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Wait-list control group (WLC)
Number of subjects: 200
Study: 28121935

Group type: EXPERIMENTAL
Intervention: Citicoline therapy at 0.6 g/d for 1 year
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no central nervous system drugs except sleeping pills and antidepressants)
Number of subjects: 30
Study: 25731140

Group type: EXPERIMENTAL
Intervention: Counseling training of nurses (motivational interviewing and stages of change model)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Control group (no counseling training)
Number of subjects: 188
Study: 22692126

Group type: EXPERIMENTAL
Intervention: Motivational music
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Rhythm beats derived from the same songs
Number of subjects: 10

Group type: COMPARATOR
Intervention: Recovery without music
Number of subjects: 10
Study: 21599615

Group type: EXPERIMENTAL
Intervention: Non-linear frequency compression (NLFC)
Number of subjects: 15
Study: 19663098

Group type: EXPERIMENTAL
Intervention: SPFDP plus ARCAU
Number of subjects: 124

Group type: COMPARATOR
Intervention: ARCAU
Number of subjects: 124
Study: 16685052

Group type: EXPERIMENTAL
Intervention: Grapefruit juice (GFJ) 240 mL with felodipine 10 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Orange juice 240 mL with felodipine 10 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Furanocoumarin-free grapefruit juice 240 mL with felodipine 10 mg
Number of subjects: 18
Study: 15474877

Group type: EXPERIMENTAL
Intervention: Sodium-restricted diet (2000 to 2400 mg/d) with restriction of total fluids to 1.5 L/d
Number of subjects: 65

Group type: COMPARATOR
Intervention: Traditional medical treatment and general nutritional recommendations
Number of subjects: 65
Study: 11755608

Group type: EXPERIMENTAL
Intervention: Ofloxacin 400 mg once daily for 10 days
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 9892527

Group type: EXPERIMENTAL
Intervention: Polymyxin B-immobilized fibre (PMX-F) treatment
Number of subjects: 24
Study: 8175223

Group type: EXPERIMENTAL
Intervention: Delay of peak velocity measurement
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Velocity of flow propagation measurement
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Correlation between methods
Number of subjects: 32
Study: 2738584

Group type: EXPERIMENTAL
Intervention: Subcutaneous hepatitis B vaccine
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Intradermal hepatitis B vaccine
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Anti-HIV positive adults
Number of subjects: 78
Study: 30384780

Group type: EXPERIMENTAL
Intervention: Caregiver-mediated exercises
Number of subjects: 14
Study: 30913978

Group type: EXPERIMENTAL
Intervention: Recalled microaggression
Number of subjects: 508

Group type: COMPARATOR
Intervention: Control event
Number of subjects: 508
Study: 29061295

Group type: EXPERIMENTAL
Intervention: eBEACOPP (8×eBEACOPP)
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: R-eBEACOPP (8×R-eBEACOPP)
Number of subjects: 434

Group type: COMPARATOR
Intervention: eBEACOPP (6×eBEACOPP)
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: 4×eBEACOPP
Number of subjects: 434

Group type: COMPARATOR
Intervention: 8×eBEACOPP
Number of subjects: 434
Study: 26164414

Group type: EXPERIMENTAL
Intervention: Neurofeedback group (NFG)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Waiting list control group (WLG)
Number of subjects: 27
Study: 23221624

Group type: EXPERIMENTAL
Intervention: 24 weeks of targeted training (3 times a week)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 55
Study: 21364482

Group type: EXPERIMENTAL
Intervention: Carbohydrate and protein solution (CHO + P) providing 0.49 and 0.16 g·kg(‐1)·h(‐1)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Carbohydrate solution (CHO) providing 0.49 g·kg(‐1)·h(‐1)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Carbohydrate solution (CHO)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Carbohydrate and protein solution (CHO + P)
Number of subjects: 8
Study: 18634158

Group type: EXPERIMENTAL
Intervention: 200 mg/day prasterone for 6 months
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: 200 mg/day prasterone for 18 months
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: 100 mg/day prasterone for 18 months
Number of subjects: 155
Study: 16926664

Group type: EXPERIMENTAL
Intervention: Comprehensive lifestyle intervention programme (regular physical activity, low fat diet, smoking cessation)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Usual care with routine follow-up
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Physical performance
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Smoking status (smokers vs non-smokers)
Number of subjects: 197
Study: 11935108

Group type: EXPERIMENTAL
Intervention: Clinical-rehabilitation intervention
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Occupational intervention
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Sherbrooke model (combination of clinical-rehabilitation and occupational interventions)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 104
Study: 10412300

Group type: EXPERIMENTAL
Intervention: Systemic palliative chemotherapy with 5-fluorouracil and leucovorin
Number of subjects: 0
Study: 7549760

Group type: EXPERIMENTAL
Intervention: Trained health workers (HWs) conducting oral visual inspections
Number of subjects: 17812

Group type: EXPERIMENTAL
Intervention: Trained health workers (HWs)
Number of subjects: 17812

Group type: COMPARATOR
Intervention: Control group (untrained HWs)
Number of subjects: 17812
Study: 2247650

Group type: EXPERIMENTAL
Intervention: Fractionated TBI regimens (12 to 15 Gy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 12 Gy fractionated scheme (6 X 2 Gy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard 10 Gy single dose TBI
Number of subjects: 0
Study: 7470371

Group type: EXPERIMENTAL
Intervention: Nicotine 500 μg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nicotine 750 μg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Range of nicotine doses from 12.5 to 800 μg
Number of subjects: 12
Study: 6403254

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy consisting of cis‐platinum 40 mg/m2 IV on day 1, adriamycin 40 mg/m2 IV on day 1, and hexamethylmelamine 150 mg/m2 PO on days 2‐10 up to a maximum of 200 mg on a 4‐weekly cycle.
Number of subjects: 53

Group type: COMPARATOR
Intervention: Moderate‐dose cyclophosphamide alone 40 mg/kg given IV intermittently every 3 weeks.
Number of subjects: 53
Study: 30632428

Group type: EXPERIMENTAL
Intervention: Continuous epidural anesthesia
Number of subjects: 98

Group type: COMPARATOR
Intervention: Local infiltration anesthesia
Number of subjects: 98
Study: 30420965

Group type: EXPERIMENTAL
Intervention: Muscle reinforcement training (RESISTANCE)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Postural training (POSTURAL)
Number of subjects: 72
Study: 28065179

Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation (1.5 g/d n-3 LCPUFA)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Olive oil (OO) supplementation
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation
Number of subjects: 103
Study: 24519847

Group type: EXPERIMENTAL
Intervention: Habit reversal treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait list control
Number of subjects: 0
Study: 21664779

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Neoadjuvant endocrine therapy (NAE)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Concentric shrinkage (CS)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Dendritic shrinkage (DS)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Comparison of shrinkage patterns
Number of subjects: 57
Study: 20051135

Group type: EXPERIMENTAL
Intervention: MF‐DPI 400 microg once‐daily in the evening
Number of subjects: 1233

Group type: COMPARATOR
Intervention: MF‐DPI 200 microg twice‐daily
Number of subjects: 1233

Group type: EXPERIMENTAL
Intervention: Self-reports for MF‐DPI 400 microg once‐daily
Number of subjects: 1233

Group type: COMPARATOR
Intervention: Self-reports for MF‐DPI 200 microg twice‐daily
Number of subjects: 1233
Study: 17118597

Group type: EXPERIMENTAL
Intervention: Sulpiride (50 mg/8 h)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Sulpiride (50 mg/8 h) plus Hydroxyzine (25 mg/12 h)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 150
Study: 16244511

Group type: EXPERIMENTAL
Intervention: Personalized psychomotor fitness program (aerobic exercise and weight training)
Number of subjects: 199

Group type: COMPARATOR
Intervention: General program of psychomotor therapy (different forms of physical exercises and relaxation training)
Number of subjects: 199
Study: 11838838

Group type: EXPERIMENTAL
Intervention: keliximab 40 mg twice weekly (bw)
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: keliximab 80 mg bw
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: keliximab 140 mg bw
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: keliximab 240 mg once weekly (ow)
Number of subjects: 322

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: keliximab 120 mg bw
Number of subjects: 322
Study: 10401918

Group type: EXPERIMENTAL
Intervention: Fluoxetine, 20 mg/day
Number of subjects: 299
Study: 7573902

Group type: EXPERIMENTAL
Intervention: Group I (without renal dysfunction)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Group II (with renal dysfunction)
Number of subjects: 30
Study: 2405733

Group type: EXPERIMENTAL
Intervention: Oral caffeine (300 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 6107674

Group type: EXPERIMENTAL
Intervention: Oral anticoagulant therapy
Number of subjects: 878

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 878
Study: 31427637

Group type: EXPERIMENTAL
Intervention: Nurse-led follow-up and medical titration by telephone to reach set intervention targets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0